European Pharmaceutical Review
DECEMBER 4, 2023
These insights help to drive highly efficient manufacturing processes, ensuring competitive product delivery on time and within budget. However, historically, NMR instruments have rarely been deployed during the later stages of pilot testing and manufacturing operations, even when driven by PAT setups.
Pharmaceutical Technology
JULY 28, 2022
FDI experts at Investment Monitor have highlighted the following list of factors as most important to life sciences companies considering a greenfield investment in 2022: labour, education, industry clusters, domestic market, infrastructure, business environment, costs and quality of life. appeared first on Pharmaceutical Technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 28, 2022
M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. However, as we near the end of the year, there were some big moves.
European Pharmaceutical Review
SEPTEMBER 29, 2022
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.
Medico Reach
FEBRUARY 8, 2023
The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. from 2022 to 2030, the pharma industry will reach USD 9,241.34 billion in 2022 and will expand at a CAGR of 10.3%
PM360
APRIL 25, 2023
Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry. When broken out by therapeutic area, 76% percent of rheumatologists reported that they were “very familiar” with biosimilar products—a 43% increase over the 2022 survey.
pharmaphorum
JANUARY 24, 2023
Over the last 25 years, the headcount in the medicines manufacturing sector has fallen by 7,000 and since 2009 production volumes have fallen by nearly a third (29%), suggesting “faltering attractiveness” of the UK for manufacturing. ” Image from the Association of the British Pharmaceutical Industry (ABPI).
Expert insights. Personalized for you.
87 
Let's personalize your content